Seal Karen H, Currie Sue L, Shen Hui, Anand Bhupinderjit S, Bini Edmund J, Brau Norbert, Jeffers Lennox, Wright Teresa L
VA Medical Center, San Francisco, CA 94121, USA.
J Clin Gastroenterol. 2007 Feb;41(2):199-205. doi: 10.1097/01.mcg.0000212644.82853.51.
BACKGROUND/GOALS: Many patients with a history of injection drug use (IDU) are excluded from hepatitis C virus (HCV) treatment. This prospective multicenter study aimed to determine the impact of IDU history on HCV treatment candidacy and outcomes.
Between 1999 and 2001, 4318 HCV-infected patients seen at 24 VA Medical Centers were evaluated for HCV treatment candidacy and followed prospectively. Univariate and multivariate logistic regression analyses were used to determine whether an IDU history was associated with HCV treatment candidacy, HCV treatment acceptance, early treatment discontinuation, and virologic response.
Of 4318 participants, 2611 (61%) reported an IDU history. IDU history was not significantly associated with HCV treatment candidacy, acceptance, early discontinuation of therapy, or virologic response (all P values nonsignificant). Instead, reduced HCV treatment candidacy was independently associated with low-income [odds ratio (OR)=1.46, 95% confidence interval (CI)=1.22-1.74), education < or = 12 years (OR=1.23, 95% CI=1.03-1.46), and alcohol consumption > or = 3 drinks/d (OR=2.08, 95% CI=1.68-2.57), whereas early discontinuation of HCV therapy was independently associated with low-income and consuming > or = 3 alcoholic drinks/d.
A history of IDU was not associated with HCV treatment candidacy or outcomes, supporting national guidelines to evaluate former IDUs on a case-by-case basis for HCV treatment.
背景/目标:许多有注射吸毒史(IDU)的患者被排除在丙型肝炎病毒(HCV)治疗之外。这项前瞻性多中心研究旨在确定IDU病史对HCV治疗候选资格和治疗结果的影响。
在1999年至2001年期间,对在24家退伍军人事务医疗中心就诊的4318例HCV感染患者进行了HCV治疗候选资格评估,并进行了前瞻性随访。采用单因素和多因素逻辑回归分析来确定IDU病史是否与HCV治疗候选资格、HCV治疗接受情况、早期治疗中断和病毒学应答相关。
在4318名参与者中,2611名(61%)报告有IDU病史。IDU病史与HCV治疗候选资格、接受情况、早期治疗中断或病毒学应答均无显著相关性(所有P值均无统计学意义)。相反,HCV治疗候选资格降低与低收入独立相关[比值比(OR)=1.46,95%置信区间(CI)=1.22-1.74]、教育程度≤12年(OR=1.23,95%CI=1.03-1.46)以及饮酒量≥3杯/天(OR=2.08,95%CI=1.68-2.57),而HCV治疗的早期中断与低收入和饮酒量≥3杯/天独立相关。
IDU病史与HCV治疗候选资格或治疗结果无关,支持国家指南对既往有IDU史的患者逐案评估HCV治疗。